Seegene Inc. and Springer Nature Partner for PCR Innovation

Seegene Inc., a leading South Korean company specializing in PCR molecular diagnostics, has joined forces with Springer Nature, a renowned scientific journal publisher, to enhance PCR diagnostic testing across various disease areas. This strategic partnership aims to leverage the combined expertise and resources of both companies to accelerate the development of innovative diagnostic products.

The collaboration between Seegene and Springer Nature is focused on supporting global researchers in their quest to create cutting-edge diagnostic solutions. By providing funding and technology to scientists in diverse fields, the partnership seeks to broaden the range of available diagnostic tools.

Building on the success of their previous Open Innovation Program, which was launched in 2023, the joint initiative led by senior management from both companies aims to drive forward the development of state-of-the-art diagnostic products through collaboration with the scientific community.

Seegene and Springer Nature plan to strengthen their cooperation through the SG OneSystem™ business, which involves identifying potential partners and hosting annual symposiums. The ultimate goal is to enhance business success and contribute to the global efforts in combating diseases.

Dr. Jong-Yoon Chun, CEO of Seegene, expressed excitement about the partnership, highlighting the shared commitment to creating a disease-free world. Similarly, Frank Vrancken Peeters, CEO of Springer Nature, commended Seegene's dedication to democratizing early disease diagnosis.

The companies have received significant interest from the scientific community for their Open Innovation Program, with a high number of applications from various countries. The 2024 program aims to expedite the commercialization of expertise and knowledge across different fields, moving away from predefined product development.

Seegene's expertise in syndromic quantitative PCR technologies, particularly showcased during the COVID-19 pandemic, has played a crucial role in providing millions of tests globally. With over 180 years of experience in advancing discovery, Springer Nature aims to continue supporting researchers and institutions in their pursuit of new ideas and impactful research.

Seegene's SG OneSystem™ business strategy focuses on sharing PCR molecular diagnostics technology worldwide to establish a consortium for developing PCR products. Through collaborations with Microsoft and Springer Nature, Seegene aims to democratize access to PCR testing and contribute to a disease-free world.

The partnership between Seegene Inc. and Springer Nature marks a significant step towards advancing PCR molecular diagnostics and fostering global collaboration in the fight against diseases. By combining their strengths and resources, these two industry leaders are poised to drive innovation and make a meaningful impact on healthcare worldwide.